Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion?
The mechanism by which long-term exposure of the beta-cell to elevated concentrations of fatty acid alters glucose-induced insulin secretion has been examined. Exposure of INS-1 beta-cells to 0.4 mmol/l oleate for 72 h increased basal insulin secretion and decreased insulin release in response to high glucose, but not in response to agents acting at the level of the K(ATP) channel (tolbutamide) or beyond (elevated KCl). This also suppressed the glucose-induced increase in the cellular ATP-to-ADP ratio. The depolarization of the plasma membrane promoted by glucose was decreased after oleate exposure, whereas the response to KCl was unchanged. Cells exposed to free fatty acids displayed a lower mitochondrial membrane potential and a decreased glucose-induced hyperpolarization. The possible implication of uncoupling protein (UCP)-2 in the altered secretory response was examined by measuring UCP2 gene expression after chronic exposure of the cells to fatty acids. UCP2 mRNA and protein were increased twofold by oleate. Palmitate and the nonoxidizable fatty acid bromopalmitate had similar effects on UCP2 mRNA, suggesting that UCP2 gene induction by fatty acids does not require their metabolism. The data are compatible with a role of UCP2 and partial mitochondrial uncoupling in the decreased secretory response to glucose observed after chronic exposure of the beta-cell to elevated fatty acids, and suggest that the expression and/or activity of the protein may modulate insulin secretion in response to glucose.
Lameloise
N
N
Department of Medical Biochemistry, Centre Médical Universitaire, Medical Faculty, University of Geneva, Switzerland.
Muzzin
P
P
Prentki
M
M
Assimacopoulos-Jeannet
F
F
D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D001790:Blood Physiological Phenomena; D002460:Cell Line; D005227:Fatty Acids / Q000378:metabolism* / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D005947:Glucose / Q000502:physiology*; D007328:Insulin / Q000378:metabolism*; D007329:Insulin Antagonists / Q000494:pharmacology; D000078790:Insulin Secretion; D007425:Intracellular Membranes / Q000502:physiology; D007473:Ion Channels; D007515:Islets of Langerhans / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D026901:Membrane Transport Proteins; D008928:Mitochondria / Q000502:physiology; D024101:Mitochondrial Proteins; D019301:Oleic Acid / Q000494:pharmacology; D011506:Proteins / Q000235:genetics / Q000502:physiology*; D013997:Time Factors; D000071246:Uncoupling Protein 2
D005227:Fatty Acids; D007328:Insulin; D007329:Insulin Antagonists; D007473:Ion Channels; D026901:Membrane Transport Proteins; D024101:Mitochondrial Proteins; D011506:Proteins; D000071246:Uncoupling Protein 2; D019301:Oleic Acid; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D005947:Glucose